Diabetic retinopathy: reversibility of epigenetic modifications and new therapeutic targets

In recent years, considerable progress has been made in the molecular mechanisms of epigenetics in disease development and progression, the reversible characteristics of epigenetic modification provide new insights for the treatment of such diseases. The pathogenesis of diabetic retinopathy (DR) has...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xinyuan, Zhao, Lin, Hambly, Brett, Bao, Shisan, Wang, Kaiyue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557533/
https://www.ncbi.nlm.nih.gov/pubmed/28815013
http://dx.doi.org/10.1186/s13578-017-0167-1
_version_ 1783257224636792832
author Zhang, Xinyuan
Zhao, Lin
Hambly, Brett
Bao, Shisan
Wang, Kaiyue
author_facet Zhang, Xinyuan
Zhao, Lin
Hambly, Brett
Bao, Shisan
Wang, Kaiyue
author_sort Zhang, Xinyuan
collection PubMed
description In recent years, considerable progress has been made in the molecular mechanisms of epigenetics in disease development and progression, the reversible characteristics of epigenetic modification provide new insights for the treatment of such diseases. The pathogenesis of diabetic retinopathy (DR) has not yet been fully understood, treatment of refractory and recurrent diabetic macular edema remains a big change in clinical practice. This review emphasizes that reversibility of epigenetic modification could provide a new strategy for the prevention and treatment of diseases.
format Online
Article
Text
id pubmed-5557533
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55575332017-08-16 Diabetic retinopathy: reversibility of epigenetic modifications and new therapeutic targets Zhang, Xinyuan Zhao, Lin Hambly, Brett Bao, Shisan Wang, Kaiyue Cell Biosci Review In recent years, considerable progress has been made in the molecular mechanisms of epigenetics in disease development and progression, the reversible characteristics of epigenetic modification provide new insights for the treatment of such diseases. The pathogenesis of diabetic retinopathy (DR) has not yet been fully understood, treatment of refractory and recurrent diabetic macular edema remains a big change in clinical practice. This review emphasizes that reversibility of epigenetic modification could provide a new strategy for the prevention and treatment of diseases. BioMed Central 2017-08-15 /pmc/articles/PMC5557533/ /pubmed/28815013 http://dx.doi.org/10.1186/s13578-017-0167-1 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Zhang, Xinyuan
Zhao, Lin
Hambly, Brett
Bao, Shisan
Wang, Kaiyue
Diabetic retinopathy: reversibility of epigenetic modifications and new therapeutic targets
title Diabetic retinopathy: reversibility of epigenetic modifications and new therapeutic targets
title_full Diabetic retinopathy: reversibility of epigenetic modifications and new therapeutic targets
title_fullStr Diabetic retinopathy: reversibility of epigenetic modifications and new therapeutic targets
title_full_unstemmed Diabetic retinopathy: reversibility of epigenetic modifications and new therapeutic targets
title_short Diabetic retinopathy: reversibility of epigenetic modifications and new therapeutic targets
title_sort diabetic retinopathy: reversibility of epigenetic modifications and new therapeutic targets
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557533/
https://www.ncbi.nlm.nih.gov/pubmed/28815013
http://dx.doi.org/10.1186/s13578-017-0167-1
work_keys_str_mv AT zhangxinyuan diabeticretinopathyreversibilityofepigeneticmodificationsandnewtherapeutictargets
AT zhaolin diabeticretinopathyreversibilityofepigeneticmodificationsandnewtherapeutictargets
AT hamblybrett diabeticretinopathyreversibilityofepigeneticmodificationsandnewtherapeutictargets
AT baoshisan diabeticretinopathyreversibilityofepigeneticmodificationsandnewtherapeutictargets
AT wangkaiyue diabeticretinopathyreversibilityofepigeneticmodificationsandnewtherapeutictargets

Ejemplares similares